The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy
Cotter TG1, Jensen DM2. Drug Des Devel Ther. 2019 Jul 29;13:2565-2577. doi: 10.2147/DDDT.S172512. eCollection 2019.
Author information
1 Center for Liver Diseases, The University of Chicago Medicine, Chicago, IL, USA.
2 Section of Hepatology, RUSH University Medical Center, Chicago, IL, USA.
Abstract
Direct-acting antiviral (DAA) therapy has changed the landscape of hepatitis C virus (HCV) management and has changed the focus to the possibility of HCV elimination in the near future. Glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor, have addressed many of the existing shortcomings in the DAA therapy spectrum. This combination has proven to be a highly efficacious pan-genotypic DAA with a high barrier to resistance as a once-daily, all-oral medication. This review explores the design and development of glecaprevir and pibrentasvir, its place in current HCV management in the midst of a myriad of DAA therapy options, and also remaining challenges.